Old Web
English
Sign In
Acemap
>
authorDetail
>
D. Saurigny
D. Saurigny
Takeda Pharmaceutical Company
Namilumab
Rheumatoid arthritis
Monoclonal antibody
Medicine
Internal medicine
3
Papers
60
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
2019
Arthritis Research & Therapy
Taylor Pc
D. Saurigny
Vencovský J
Tsutomu Takeuchi
Nakamura T
Matsievskaia G
Hunt B
T. Wagner
B. Souberbielle
Show All
Source
Cite
Save
Citations (31)
Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis
2017
Arthritis Research & Therapy
T. W. J. Huizinga
A. Batalov
R Stoilov
Eric E. Lloyd
T. Wagner
D. Saurigny
B. Souberbielle
E. Esfandiari
Show All
Source
Cite
Save
Citations (24)
SAT0210 First-in-Patient Study of Namilumab, an Anti-GM-CSF Monoclonal Antibody, in Active Rheumatoid Arthritis: Results of the Priora Phase IB Study
2015
Annals of the Rheumatic Diseases
T. W. J. Huizinga
A. Batalov
K. Yablanski
R Stoilov
E. Lloyd
T. Wagner
D. Saurigny
B. Souberbielle
E. Esfandiari
Show All
Source
Cite
Save
Citations (5)
1